 |
|
JAMA-EXPRESS
Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics
The PCI-CLARITY Study
Marc S. Sabatine, MD, MPH;
Christopher P. Cannon, MD;
C. Michael Gibson, MD, MS;
Jose L. López-Sendón, MD;
Gilles Montalescot, MD, PhD;
Pierre Theroux, MD;
Basil S. Lewis, MD;
Sabina A. Murphy, MPH;
Carolyn H. McCabe, BS;
Eugene Braunwald, MD; for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
JAMA. 2005;294:1224-1232.
ABSTRACT
| |
Context The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted.
Objective To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events.
Design, Setting, and Participants The PCI-Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study was a prospectively planned analysis of the 1863 patients undergoing PCI after mandated angiography in CLARITY–Thrombolysis in Myocardial Infarction (TIMI) 28, a randomized, double-blind, placebo-controlled trial of clopidogrel in patients receiving fibrinolytics for STEMI. Patients were enrolled at 319 sites in 23 countries from February 2003 through October 2004.
Interventions Patients received aspirin and were randomized to receive either clopidogrel (300 mg loading dose, then 75 mg once daily) or placebo initiated with fibrinolysis and given until coronary angiography, which was performed 2 to 8 days after initiation of the study drug. For patients undergoing coronary artery stenting, it was recommended that open-label clopidogrel (including a loading dose) be administered after the diagnostic angiogram.
Main Outcome Measures The primary outcome was the incidence of the composite of cardiovascular death, recurrent MI, or stroke from PCI to 30 days after randomization. Secondary outcomes included MI or stroke before PCI and the aforementioned composite from randomization to 30 days.
Results Pretreatment with clopidogrel significantly reduced the incidence of cardiovascular death, MI, or stroke following PCI (34 [3.6%] vs 58 [6.2%]; adjusted odds ratio [OR], 0.54 [95% CI, 0.35-0.85]; P = .008). Pretreatment with clopidogrel also reduced the incidence of MI or stroke prior to PCI (37 [4.0%] vs 58 [6.2%]; OR, 0.62 [95% CI, 0.40-0.95]; P = .03). Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23). There was no significant excess in the rates of TIMI major or minor bleeding (18 [2.0%] vs 17 [1.9%]; P>.99).
Conclusions Clopidogrel pretreatment significantly reduces the incidence of cardiovascular death or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding. These data add further support to the early use of clopidogrel in STEMI and the strategy of routine clopidogrel pretreatment in patients undergoing PCI.
INTRODUCTION
Platelet activation plays a critical role both in spontaneous coronary artery thrombosis due to atherosclerotic plaque rupture and in thrombotic complications following percutaneous coronary intervention (PCI) with coronary artery stenting. For that reason, aspirin is part of the standard treatment given to patients with coronary artery disease, including those undergoing PCI.1
Dual antiplatelet therapy following PCI, using a combination of a P2Y12 adenosine diphosphate receptor blocker (such as ticlopidine or clopidogrel) and aspirin, further reduces platelet activation and thrombotic and ischemic complications.2-4 However, the optimal timing of the initiation of clopidogrel has been debated. Specifically, the benefit of routine clopidogrel pretreatment started hours to days before PCI compared with treatment given at the time of PCI in high-risk patients with acute coronary syndromes remains incompletely defined, and hence current guidelines do not universally recommend pretreatment.1, 5-6
In the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in Myocardial Infarction (TIMI) 28 trial, patients with ST-segment elevation myocardial infarction (STEMI) receiving a fibrinolytic were randomized on presentation to receive clopidogrel (including a loading dose) or placebo.7 Per protocol, all patients were to undergo angiography after 2 to 8 days, and this design created the opportunity to study clopidogrel pretreatment given in a standardized fashion. Accordingly, PCI-CLARITY was a prespecified test of the hypothesis that in patients undergoing PCI after initial pharmacological therapy for STEMI, clopidogrel pretreatment hours to days before PCI is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events.
METHODS
Patient Population
The PCI-CLARITY study was a planned subanalysis of patients undergoing PCI who were randomized to receive clopidogrel or placebo at presentation in the CLARITY-TIMI 28 trial.7 As described previously,8 men and women 18 to 75 years of age were eligible for inclusion if they had all of the following: onset of ischemic discomfort at rest 12 hours or less prior to randomization and lasting longer than 20 minutes; ST-segment elevation at least 0.1 mV in at least 2 contiguous limb leads or at least 0.2 mV in at least 2 contiguous precordial leads, or left bundle-branch block not known to be old; and planned treatment with a fibrinolytic, an anticoagulant (if receiving a fibrin-specific lytic), and aspirin.
Excluded from the main CLARITY-TIMI 28 trial were patients (1) treated with clopidogrel within 7 days prior to enrollment or in whom treatment with clopidogrel or a glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitor before angiography was planned; (2) who had contraindications to fibrinolysis; (3) in whom there was the intention of performing angiography within 48 hours in the absence of a new clinical indication; (4) with cardiogenic shock; (5) who had undergone prior coronary artery bypass grafting; or (6) weighing 67 kg or less who had received more than 4000 U bolus or weighing more than 67 kg who had received more than 5000 U bolus of unfractionated heparin, or who had received greater than standard doses of low-molecular-weight heparin.
The main study protocol was approved by the relevant institutional review boards, and written informed consent was obtained from all patients. Patients were enrolled at 319 sites in 23 countries from February 2003 through October 2004.
Procedures
Patients were randomized in a 1:1 ratio to receive either clopidogrel (300 mg loading dose, then 75 mg once daily) or placebo in a double-blind fashion. The loading dose was to be given within 45 minutes (and optimally within 10 minutes) of the start of fibrinolytic therapy. Patients were to receive study medication daily up to and including the day of coronary angiography.
All patients were to be treated with a fibrinolytic (selected by the treating physician), aspirin (recommended dose of 150-325 mg on the first day and 75-162 mg daily thereafter), and, for those receiving a fibrin-specific lytic, heparin for 48 hours. The recommended unfractionated heparin dosing was 60 U/kg intravenous bolus (maximum 4000 U) followed by an infusion at 12 U/kg/h (maximum 1000 U/h).9 Use of low-molecular-weight heparin at established doses instead of unfractionated heparin and use of heparin in patients receiving streptokinase was at the discretion of the treating physician.
Coronary angiography was required by protocol in all patients and was to be performed 48 to 192 hours after starting the study medication to determine patency of the infarct-related artery. Angiography before 48 hours was permitted only if clinically indicated.8-9 Percutaneous coronary intervention was done at the discretion of the local investigator. For patients who underwent coronary stenting, it was recommended that open-label clopidogrel be administered after the diagnostic angiogram with a loading dose of at least 300 mg, followed by 75 mg daily. Use of a GpIIb/IIIa inhibitor was not permitted before coronary angiography unless clinically indicated, but was allowed after the diagnostic coronary angiogram was obtained.
Patients were followed up for clinical outcomes and adverse events during their index hospitalization. Patients undergoing PCI were to have creatine kinase (CK)-MB measured 3 times over the 24 hours following PCI to ensure systemic monitoring for post-PCI MI. Telephone follow-up was performed 30 days after randomization to assess for clinical outcomes or adverse events, which were verified using medical records. Follow-up was complete in 1862 (99.9%) of the 1863 patients who underwent PCI.
Outcomes
The primary efficacy outcome for this analysis was the composite of cardiovascular death, recurrent MI, or stroke from PCI to 30 days after randomization. Secondary outcomes included recurrent MI or stroke before PCI and the composite of cardiovascular death, recurrent MI, or stroke from randomization to 30 days. Recurrent MI within 24 hours after a PCI was prospectively defined as needing to meet one of the following 3 criteria: (1) CK-MB value (or total CK value if CK-MB not available) of at least 3 x upper limit of normal and, if the pre-PCI CK-MB (or total CK) value was greater than the upper limit of normal, both an increase by at least 50% over the previous value and documentation that the CK-MB (or totalCK) value was decreasing prior to the suspected recurrent MI; or (2) development of new, abnormal Q waves in 2 or more contiguous leads; or (3) pathological findings of an acute MI thought to be distinct from the qualifying MI.8 The primary safety outcome for this analysis was the rate of TIMI major or minor bleeding10 from PCI to 30 days after randomization. All ischemic and any clinically significant bleeding events were adjudicated by an independent clinical events committee that was blinded to treatment assignment.
Statistical Analysis
All efficacy analyses were based on the intention-to-treat principle. For patients who underwent more than 1 PCI, the first PCI was counted as the index procedure. For comparing baseline characteristics, differences in continuous variables were analyzed using t tests, and differences in categorical variables were analyzed using the Fisher exact test. Efficacy outcome analyses were performed using a logistic regression model that included terms for treatment group, type of fibrinolytic, initial type of heparin, infarct location, and a propensity score for PCI. A propensity score allows for adjustment for potential selection bias when comparing the effect of randomized treatment allocation within a subset of patients.11-12 The propensity score was constructed by applying a forward selection algorithm with an inclusion P value threshold of <.05 to a logistic regression model predicting PCI in the entire trial cohort and containing candidate baseline variables that included demographics, country, traditional cardiovascular risk factors, prior cardiac disease and procedures, cardiac medications, time to presentation, initial vital signs, infarct location, type of lytic, initial type of heparin, and treatment allocation. The final propensity score included terms for country, race (self-reported), prior MI, prior PCI, systolic blood pressure and heart rate at presentation, time from symptom onset to administration of fibrinolytic, type of fibrinolytic, and type of initial heparin. (For this trial there will be a substudy funded by the National Institutes of Health [NIH], and collection of data on race is an NIH requirement.) Time-to-first-event curves were generated using the Kaplan-Meier method and were compared using a Cox proportional hazards model with the same covariates as used in the logistic regression model. The proportional hazards assumption was confirmed by checking the Schoenfeld residuals. Safety outcomes were analyzed according to the treatment actually received by each patient, and rates were compared using the Fisher exact test.
A meta-analysis of the results of the PCI-CLARITY, PCI-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE),13 and Clopidogrel for the Reduction of Events During Observation (CREDO)14 studies was performed. Summary data on the rates of cardiovascular death and MI were abstracted from the publications of the other 2 trials and verified by the trial sponsors. Odds ratios (ORs) and 95% confidence intervals (CIs) for the effect of clopidogrel pretreatment vs no pretreatment on the incidence of MI before PCI and cardiovascular death or MI up to 30 days following PCI were calculated for each trial. The results from trials were combined using a random-effects model that used weighting based on inverse variance.15 Between-trial heterogeneity was assessed using  2 tests. All statistical analyses were performed using Stata/SE, version 8.2 (StataCorp LP, College Station, Tex).
RESULTS
Overall, 1863 (53.4%) of the 3491 patients enrolled in the CLARITY-TIMI 28 trial underwent PCI during the index hospitalization. The rates of PCI were equivalent in the 2 treatment arms. Thus, of 1863 patients who underwent PCI, 933 (50.1%) had been randomized to receive clopidogrel and 930 (49.9%) had been randomized to receive placebo at the time of initial presentation (Figure 1). The 2 treatment groups were well-matched with regard to baseline characteristics (Table 1), with no statistically significant differences. Seventy-nine percent of patients received a fibrin-specific lytic, and the remainder received streptokinase. Ninety-nine percent of patients received aspirin and 89% received heparin.
|
|
|
|
Figure 1. Study Profile
CABG indicates coronary artery bypass grafting; PCI, percutaneous coronary intervention.
|
|
|
|
|
|
|
Table 1. Baseline Characteristics and Treatment of Patients*
|
|
|
The median number of days from initiation of the study drug to PCI was 3 days (Table 2). Immediately prior to PCI, the infarct-related artery was patent in 806 patients (86.9%) in the clopidogrel pretreatment arm and in 748 patients (80.8%) in the placebo arm (P<.001). Following PCI, 99% of patients in both groups had a patent infarct-related artery. Approximately one third of patients received a GpIIb/IIIa inhibitor at the time of PCI, and 95% of patients received a stent. Slightly more than three quarters of patients received a loading dose of an open-label thienopyridine at the time of PCI, and 90% of patients received a maintenance dose of an open-label thienopyridine after PCI.
|
|
|
|
Table 2. Percutaneous Coronary Intervention (PCI) Characteristics*
|
|
|
Pretreatment with clopidogrel significantly reduced the rate of cardiovascular death, recurrent MI, or stroke following PCI through 30 days after randomization (34 [3.6%] vs 58 [6.2%]; adjusted OR, 0.54 [95% CI, 0.35-0.85]; P = .008; number needed to treat = 39) (Table 3). The benefit of clopidogrel pretreatment was directionally consistent among all of the components of the composite end point, with the adjusted ORs for cardiovascular death (0.49 [95% CI, 0.24-1.03]), recurrent MI (0.60 [95% CI, 0.33-1.11]), and stroke (0.35 [95% CI, 0.11-1.11]) all favoring pretreatment. Inspection of the Kaplan-Meier estimated event rate curves for cardiovascular death, recurrent MI, or stroke over time for the 2 treatment groups revealed that they separated soon after PCI and continued to diverge over time (Figure 2).
|
|
|
|
Table 3. Major Cardiovascular Outcomes*
|
|
|
|
|
|
|
Figure 2. Incidence of Cardiovascular End Points Before and After Percutaneous Coronary Intervention (PCI)
P values are derived from a Cox proportional hazards model as described in the "Methods."
|
|
|
The effect of clopidogrel pretreatment on reducing cardiovascular death and ischemic events after PCI was consistent across a wide range of important subgroups (Figure 3). Specifically, in terms of baseline characteristics, clopidogrel pretreatment was beneficial regardless of patient age, sex, presence of diabetes mellitus, or infarct location. The benefit of pretreatment was also similar whether patients underwent PCI urgently for recurrent ischemia or electively, and irrespective of the timing of PCI relative to randomization. The benefit was also consistent regardless of the predominant type of heparin the patient received while awaiting angiography and whether a GpIIb/IIIa inhibitor or a loading dose of open-label clopidogrel was given at the time of PCI.
|
|
|
|
Figure 3. Rates of and Odds Ratios (ORs) for Cardiovascular Death, Recurrent Myocardial Infarction, and Stroke Following Percutaneous Coronary Intervention (PCI) up to 30 Days After Randomization Overall and in Various Subgroups
Subgroup analyses are based on available data for each characteristic. The overall treatment effect is represented by the diamond, the left and right borders of which indicate the 95% confidence interval (CI). The vertical dashed line represents the overall treatment effect. The squares indicate the adjusted ORs and the size of each square is proportional to the number of patients in the individual analysis. All interaction P values were nonsignificant. Gp indicates glycoprotein; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.
|
|
|
Prior to undergoing PCI, treatment with clopidogrel significantly reduced the rate of recurrent MI or stroke (37 [4.0%] vs 58 [6.2%]; adjusted OR, 0.62 [95% CI, 0.40-0.95]; P = .03) (Table 3 and Figure 2). Overall, when the events before and after PCI are considered as a whole (Table 3), pretreatment with clopidogrel significantly reduced the incidence of cardiovascular death, recurrent MI, or stroke through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23).
There was no significant excess in the rates of TIMI major bleeding (0.5% vs 1.1%), TIMI minor bleeding (1.4% vs 0.8%), or the combination (2.0% vs 1.9%) following PCI in those who received clopidogrel pretreatment compared with those who did not (Table 4). In addition, among patients who received a GpIIb/IIIa inhibitor during PCI, the rate of TIMI major or minor bleeding was no higher in those who had received clopidogrel pretreatment (2.1% [6/283]) than in those who did not receive pretreatment (2.9% [9/307]) (P = .36).
|
|
|
|
Table 4. Safety Outcomes*
|
|
|
COMMENT
Our study demonstrates that pretreatment with clopidogrel before PCI significantly reduced by 46% the odds of cardiovascular death, recurrent MI, or stroke within 30 days following PCI. This benefit was seen in patients with STEMI treated with fibrinolytics who subsequently underwent PCI on average 3 days later, but with a consistent benefit regardless of the time from initiation of pretreatment to PCI. Moreover, benefits were seen regardless of whether patients received a GpIIb/IIIa inhibitor at the time of PCI or whether patients received a loading dose of open-label clopidogrel at the time of PCI. Despite the more intensive antiplatelet therapy, there was no significant excess in TIMI major or minor bleeding.
Clopidogrel is a prodrug that is metabolized in the liver by the cytochrome P450 system into its active form.16 In the absence of a loading dose, it takes approximately 3 to 5 days for the antiplatelet effects of 75 mg of clopidogrel daily to reach steady state. The use of a 300- to 600-mg loading dose, even in the setting of long-term therapy, greatly accelerates that process and allows substantial platelet inhibition to be achieved after several hours.17-18 However, in the setting of PCI, platelet activation is immediate19 and therefore may be incompletely suppressed if clopidogrel is initiated only at the time of PCI. In platelet aggregation studies, compared with a loading dose at the time of PCI, pretreatment with clopidogrel resulted in greater suppression of markers of platelet activation after PCI.20
Mehta and the PCI-CURE Investigators demonstrated that in patients with non–ST-elevation acute coronary syndromes undergoing PCI, pretreatment with clopidogrel reduced the risk of MI before PCI by 32% and the risk of cardiovascular death or MI after PCI to 30 days by 34%.13 Importantly, though, as the trial was conducted at sites that took a less aggressive approach toward cardiac catheterization, the median time to PCI was 10 days. Subsequent analyses suggested a consistent benefit among those undergoing PCI within 2 days vs after 2 days.21 Nonetheless, questions were raised about potential imbalances between treatment groups because the performance of angiography was at the discretion of the treating physician and not mandated by the trial protocol.22
The CREDO trial provided additional important data on the value of clopidogrel pretreatment in patients undergoing planned, elective PCI.14 In that study, Steinhubl and colleagues demonstrated that clopidogrel pretreatment was associated with a trend to a reduction in the odds of death or MI through 28 days after PCI. Analysis by the duration of pretreatment found that patients in whom clopidogrel was initiated at least 6 hours prior to PCI had a 38.6% reduction in events with a strong trend toward statistical significance (P = .051). Of note, however, following PCI all patients received only 75 mg of open-label clopidogrel. Therefore, in the CREDO trial, patients who did not receive clopidogrel pretreatment never received a loading dose of clopidogrel, which does not reflect current practice patterns.23
The PCI-CLARITY study builds on these prior studies in several important ways. First, we studied patients with STEMI and showed a benefit with clopidogrel pretreatment in these patients who are at the highest risk for early recurrent ischemic events. Clopidogrel thus appears to be an important component to include in a pharmacoinvasive approach to patients with STEMI.24-27 Second, we evaluated a broad range of durations of pretreatment from less than 6 hours to 8 days and showed a consistent benefit of clopidogrel pretreatment across this range of pretreatment durations. Of note, although the maximal effect of clopidogrel on platelet inhibition may not occur until 6 or more hours after a 300-mg loading dose,28-29 some degree of platelet inhibition can be measured as early as 90 minutes.30 Prior studies have shown that the degree of platelet inhibition at the time of PCI is strongly related to the likelihood of major adverse cardiovascular events following PCI.31 Our findings suggest that in the setting of an acute coronary syndrome with heightened platelet activation32 and PCI causing immediate and further platelet activation,33-34 even relatively brief durations of pretreatment with clopidogrel before PCI may translate into improved patient outcomes. Third, we showed a benefit with clopidogrel pretreatment regardless of whether a standard loading dose of clopidogrel was administered in the cardiac catheterization laboratory at the time of PCI. Fourth, we showed a benefit with clopidogrel pretreatment regardless of GpIIb/IIIa inhibitor use peri-PCI in patients with acute coronary syndromes. This finding is supported by results from nonrandomized comparisons in registries and in the Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) and Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE) trials,35-38 and builds on a similar observation made in the setting of elective PCI in CREDO and non-ST-elevation acute coronary syndromes in PCI-CURE.13-14
Interestingly, in the PCI-CLARITY study, the event curves following PCI continued to diverge over time despite almost all patients in both treatment groups receiving open-label clopidogrel following PCI, an observation also seen in PCI-CURE.13 This observation suggests that the beneficial effect of clopidogrel may extend beyond just prevention of platelet aggregation and myocyte necrosis during the procedure. By blocking the P2Y12 receptor, clopidogrel inhibits platelet activation and thus may have more widespread effects on endothelial cells, leukocytes, and inflammation.39 For example, clopidogrel has been shown to blunt expression of both P-selectin and CD40 ligand,20, 40 the former of which contributes to platelet-leukocyte aggregation and the latter of which can trigger an inflammatory response in endothelial cells.41-42 To that end, thienopyridine pretreatment has been shown to attenuate the rise in C-reactive protein immediately after PCI43 and to decrease the need for target vessel revascularization over 1 year.44
In terms of implications of PCI-CLARITY for clinical practice, for every 100 patients undergoing PCI in whom a strategy of clopidogrel pretreatment is adopted, approximately 2 MIs would be prevented before PCI and an additional 2 cardiovascular deaths, MIs, or strokes would be prevented after PCI to 30 days. Overall, only 23 patients would need to be pretreated with clopidogrel to prevent 1 cardiovascular death, MI, or stroke. This benefit with pretreatment is achieved when compared with the current practice in which patients receive a loading dose of clopidogrel at the time of PCI and a maintenance dose thereafter. Thus in 100 patients, 4 major cardiovascular events can be avoided simply by the use of 1 to 3 doses of clopidogrel before PCI.
Taken together, the PCI-CURE and CREDO studies, and now PCI-CLARITY, demonstrate a clear and consistent benefit with clopidogrel pretreatment for PCI (Figure 4). The significant reduction in adverse cardiovascular events before PCI suggests that a strategy of clopidogrel pretreatment should be initiated as soon as possible. Accordingly, even if clopidogrel is not given at presentation, once the decision is made to proceed with angiography, and hence possible PCI, initiation of pretreatment will maximize the benefit. The consistency of benefit of clopidogrel pretreatment across the spectrum from stable coronary artery disease to STEMI, and regardless of patient demographics or the use of a GpIIb/IIIa inhibitor at the time of PCI, should help encourage widespread incorporation of clopidogrel pretreatment into cardiology clinical pathways.
|
|
|
|
Figure 4. Meta-analysis of Clopidogrel Pretreatment in Percutaneous Coronary Intervention (PCI)
Individual trial and combined results for the effect of clopidogrel pretreatment on myocardial infarction before PCI (panel A) or cardiovascular death or myocardial infarction after PCI up to 30 days (panel B). The squares indicate the unadjusted odds ratios (ORs) and the size of each square reflects the statistical weight of a trial in calculating the OR; the horizontal lines indicate the 95% confidence intervals (CIs). Tests for heterogeneity: 21 = 0.11, P = .74 (panel A); 22= 1.37, P = .51 (panel B). CREDO indicates Clopidogrel for the Reduction of Events During Observation; PCI-CLARITY, PCI-Clopidogrel as Adjunctive Reperfusion Therapy; PCI-CURE, PCI-Clopidogrel in Unstable angina to prevent Recurrent Events. Ellipses indicate not applicable.
|
|
|
In terms of safety, we saw no increase in TIMI major or minor bleeding in PCI-CLARITY. This observation is similar to the findings in the PCI-CURE study, in which the rates of major bleeding were 1.6% in the clopidogrel treatment arm and 1.4% in the placebo treatment arm. These data, coupled with observations on the efficacy and safety of initiating clopidogrel even in patients who ultimately proceed to coronary artery bypass grafting,7, 45 suggest that rather than waiting for angiography, an empirical strategy of early clopidogrel pretreatment begun as soon as possible in patients with acute coronary syndromes, only a small minority of whom will need to undergo surgery, will be of the greatest benefit in preventing cardiovascular events.
Potential limitations of this study merit consideration. Percutaneous coronary intervention was performed at the discretion of the treating physician and was a postrandomization event. However, angiography was mandated in the CLARITY-TIMI 28 trial and was carried out in all but 4% of surviving patients. This design should have minimized any potential bias, and, in fact, in PCI-CLARITY, the rates of both angiography and PCI were identical in the 2 treatment arms. Moreover, we included a propensity score in our multivariable analyses to minimize any potential bias, although we recognize that residual confounding could still exist. Furthermore, we performed a sensitivity analysis in which we examined the magnitude of benefit of clopidogrel pretreatment in the setting of both urgent and elective PCI and found no difference. Our results do not apply to all STEMI patients undergoing PCI, as patients in the CLARITY-TIMI 28 trial were required to be treated with a fibrinolytic, which can lead to platelet activation and thus possibly enhance the benefit of more intensive antiplatelet therapy.32, 46 However, the benefit of clopidogrel pretreatment that we found was similar in magnitude to the benefit seen in patients with non–ST-elevation acute coronary syndromes13 and in patients undergoing elective PCI.14
In conclusion, we found that in high-risk patients with STEMI treated with fibrinolytic therapy, a strategy of clopidogrel pretreatment significantly reduced the incidence of cardiovascular death and ischemic complications both before and after PCI without a significant increase in major or minor bleeding. These data add further support to the early use of clopidogrel in STEMI and the broader strategy of clopidogrel pretreatment in patients undergoing PCI.
AUTHOR INFORMATION
Corresponding Author: Marc S. Sabatine, MD, MPH, Cardiovascular Division, TIMI Study Group, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (msabatine{at}partners.org).
Author Contributions: Dr Sabatine had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Sabatine, Cannon, Gibson, McCabe, Braunwald.
Acquisition of data: Cannon, López-Sendón, Montalescot, Theroux, Lewis.
Analysis and interpretation of data: Sabatine, Cannon, Gibson, Murphy, Braunwald.
Drafting of the manuscript: Sabatine, Cannon, Braunwald.
Critical revision of the manuscript for important intellectual content: Sabatine, Cannon, Gibson, López-Sendón, Montalescot, Theroux, Lewis, Murphy, McCabe, Braunwald.
Statistical analysis: Sabatine, Cannon, Murphy.
Obtained funding: Cannon, McCabe, Braunwald.
Administrative, technical, or material support: McCabe, Braunwald.
Study supervision: Sabatine, Cannon, Gibson, McCabe, Braunwald.
Financial Disclosures: Dr Sabatine has received research grant support from Bristol-Myers Squibb, has spoken at symposia sponsored by Bristol-Myers Squibb and Sanofi-Aventis, and has served on scientific advisory boards for Bristol-Myers Squibb, Sanofi-Aventis, and AstraZeneca. Dr Cannon has received research grant support from AstraZeneca, Bristol-Myers Squibb, Merck, and Sanofi-Aventis and has spoken at symposia sponsored by and served on scientific advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Guilford Pharmaceuticals, Merck, Millennium, Pfizer, Sanofi-Aventis, Schering-Plough, and Vertex. Dr Gibson has received research grant support from Bristol-Myers Squibb and Millennium, has spoken at symposia sponsored by Bristol-Myers Squibb, Genentech, and Millennium, and has served on scientific advisory boards for Genentech and Millennium. Dr López-Sendón has received grant support from Bristol-Myers Squibb and Sanofi-Aventis and has served on scientific advisory boards for AstraZeneca, Glaxo, Guidant, and Pfizer. Dr Montalescot has spoken at symposia sponsored by and has served on scientific advisory boards for Sanofi-Aventis and Bristol-Myers Squibb. Dr Theroux has spoken at symposia sponsored by and has served as a scientific consultant for Sanofi-Aventis and Bristol-Myers Squibb. Dr Lewis has spoken at symposia sponsored by and has served on scientific advisory boards for Sanofi-Aventis and Bristol-Myers Squibb. Ms McCabe has received research grant support from Bristol-Myers Squibb, Sanofi-Aventis, AstraZeneca, and Millennium. Dr Braunwald has received research grant support from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, and AstraZeneca and has spoken at symposia sponsored by Bristol-Myers Squibb. Ms Murphy did not report any disclosures.
Funding/Support: The parent trial, CLARITY-TIMI 28, was supported by the pharmaceutical partnership of Sanofi-Aventis and Bristol-Myers Squibb. Dr Sabatine is the recipient of a grant (R01 HL072879) from the National Heart, Lung, and Blood Institute.
Role of the Sponsor: The sponsors’ staff assisted in monitoring the progress of the trial. Blinded data were collected by an independent data coordinating center (Nottingham Clinical Research Group, Nottingham, England). Statistical analyses for this study were done by the TIMI Study Group. Medical and statistical specialists employed by the sponsors reviewed the manuscript.
Author Affiliations: The Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (Drs Sabatine, Cannon, Gibson, and Braunwald, and Mss Murphy and McCabe); Cardiology Department, Hospital Universitario La Paz, Madrid, Spain (Dr López-Sendón); Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France (Dr Montalescot); Department of Medicine, Montreal Heart Institute, Montreal, Quebec (Dr Theroux); and Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport School of Medicine, Haifa, Israel (Dr Lewis).
REFERENCES
| |
1. Levine GN, Kern MJ, Berger PB, et al, American Heart Association Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med. 2003;139:123-136.
FREE FULL TEXT
2. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998;97:1046-1052.
FREE FULL TEXT
3. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
FREE FULL TEXT
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
FREE FULL TEXT
5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessibility verified August 4, 2005.
6. Braunwald E. Application of current guidelines to the management of unstable angina and non–ST-elevation myocardial infarction. Circulation. 2003;108:III28-III37.
PUBMED
7. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
FREE FULL TEXT
8. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 trial. Am Heart J. 2005;149:227-233.
FULL TEXT
|
ISI
| PUBMED
9. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2004;110:e82-e292.
FREE FULL TEXT
10. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann Intern Med. 1991;115:256-265.
FREE FULL TEXT
11. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol. 1976;104:609-620.
FREE FULL TEXT
12. Joffe MM, Rosenbaum PR. Propensity scores. Am J Epidemiol. 1999;150:327-333.
FREE FULL TEXT
13. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
FULL TEXT
|
ISI
| PUBMED
14. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
FREE FULL TEXT
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
FULL TEXT
|
ISI
| PUBMED
16. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
ISI
| PUBMED
17. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
FREE FULL TEXT
18. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110:1916-1919.
FREE FULL TEXT
19. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb. 1992;12:1475-1487.
FREE FULL TEXT
20. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004;93:679-684.
FULL TEXT
|
ISI
| PUBMED
21. Lewis BS, Mehta SR, Fox KAA, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J. In press.
22. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation. 2002;106:2284-2287.
FREE FULL TEXT
23. Leopold JA, Antman EM. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Circulation. 2005;111:1097-1099.
FREE FULL TEXT
24. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA. 1988;260:2849-2858.
FREE FULL TEXT
25. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1989;320:618-627.
ABSTRACT
26. Antman EM, Van de Werf F. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction. Circulation. 2004;109:2480-2486.
FREE FULL TEXT
27. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293:979-986.
FREE FULL TEXT
28. Savcic M, Hauert J, Bachman F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25:15-19.
PUBMED
29. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93.
FREE FULL TEXT
30. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000;101:2823-2828.
FREE FULL TEXT
31. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001;103:2572-2578.
FREE FULL TEXT
32. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
ABSTRACT
33. Gawaz M, Neumann F-JJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229-237.
FREE FULL TEXT
34. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 2003;145:239-247.
FULL TEXT
|
ISI
| PUBMED
35. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672-674.
FULL TEXT
|
ISI
| PUBMED
36. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol. 2001;88:884-886.
FULL TEXT
|
ISI
| PUBMED
37. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol. 2003;42:1188-1195.
FREE FULL TEXT
38. Saw J, Lincoff AM, DeSmet W, et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol. 2004;44:1194-1199.
FREE FULL TEXT
39. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106:379-385.
FREE FULL TEXT
40. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43:1982-1988.
FREE FULL TEXT
41. Weyrich AS, Prescott SM, Zimmerman GA. Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. Circulation. 2002;106:1433-1435.
FREE FULL TEXT
42. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
FULL TEXT
| PUBMED
43. Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004;94:358-360.
FULL TEXT
|
ISI
| PUBMED
44. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403-1409.
FREE FULL TEXT
45. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-1208.
FREE FULL TEXT
46. Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation. 1989;80:1718-1725.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
David J. Moliterno and Steven R. Steinhubl
JAMA. 2005;294(10):1271-1273.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Update on dual antiplatelet therapy for percutaneous coronary intervention
Prasad and Holmes
Heart 2009;95:861-865.
FULL TEXT
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Price
Circulation 2009;119:2625-2632.
FULL TEXT
The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective
Cleanthis and Flather
Clin Risk 2009;15:106-108.
FULL TEXT
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Tousoulis et al.
Heart 2009;95:850-858.
FULL TEXT
Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery
Blasco-Colmenares et al.
Arch Intern Med 2009;169:788-795.
ABSTRACT
| FULL TEXT
Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial
Mehilli et al.
Circulation 2009;119:1933-1940.
ABSTRACT
| FULL TEXT
Long-term treatment strategies for atherothrombotic disease: do platelets define the course?
Zimarino and De Caterina
Eur Heart J Suppl 2008;10:I8-I13.
ABSTRACT
| FULL TEXT
Impact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Systematic Review
Vlaar et al.
Circulation 2008;118:1828-1836.
ABSTRACT
| FULL TEXT
Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
Kastrati et al.
NEJM 2008;359:688-696.
ABSTRACT
| FULL TEXT
Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention
Stone
Circulation 2008;118:538-551.
FULL TEXT
Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions
Stone
Circulation 2008;118:552-566.
FULL TEXT
Dual antiplatelet therapy with clopidogrel and aspirin
Sullivan and Amarshi
Am J Health Syst Pharm 2008;65:1134-1143.
ABSTRACT
| FULL TEXT
Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer?
Schiele et al.
Eur Heart J 2008;29:1475-1477.
FULL TEXT
The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Douketis et al.
Chest 2008;133:299S-339S.
ABSTRACT
| FULL TEXT
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT
| FULL TEXT
Clopidogrel Resistance: More Grist for the Mill
Cairns and Eikelboom
J Am Coll Cardiol 2008;51:1935-1937.
FULL TEXT
Unmet needs in antiplatelet therapy
Bassand
Eur Heart J Suppl 2008;10:D3-D11.
ABSTRACT
| FULL TEXT
INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
BAKHRU and BHATT
Cleveland Clinic Journal of Medicine 2008;75:289-295.
ABSTRACT
| FULL TEXT
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:210-247.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Antman et al.
Circulation 2008;117:296-329.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT
Antiplatelet therapy in acute coronary syndromes
Gitt and Betriu
Eur Heart J Suppl 2008;10:A4-A12.
ABSTRACT
| FULL TEXT
Antiplatelet therapy in percutaneous coronary intervention
Bode and Huber
Eur Heart J Suppl 2008;10:A13-A20.
ABSTRACT
| FULL TEXT
When and how to discontinue antiplatelet therapy
Bertrand
Eur Heart J Suppl 2008;10:A35-A41.
ABSTRACT
| FULL TEXT
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial
Cannon et al.
J Am Coll Cardiol 2007;50:1844-1851.
ABSTRACT
| FULL TEXT
Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals
Dobrzycki et al.
Eur Heart J 2007;28:2438-2448.
ABSTRACT
| FULL TEXT
Dual antiplatelet therapy in high-risk patients
Van de Werf
Eur Heart J Suppl 2007;9:D3-D9.
ABSTRACT
| FULL TEXT
Percutaneous Coronary Intervention in Patients Receiving Enoxaparin or Unfractionated Heparin After Fibrinolytic Therapy for ST-Segment Elevation Myocardial Infarction in the ExTRACT-TIMI 25 Trial
Gibson et al.
J Am Coll Cardiol 2007;49:2238-2246.
ABSTRACT
| FULL TEXT
Managing acute coronary syndrome: Evidence-based approaches
Spinler
Am J Health Syst Pharm 2007;64:S14-S24.
ABSTRACT
| FULL TEXT
Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2007;62:518-524.
ABSTRACT
| FULL TEXT
Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease
Maree and Fitzgerald
Circulation 2007;115:2196-2207.
FULL TEXT
Primary percutaneous coronary intervention.
Brown et al.
NEJM 2007;356:1588-1589.
FULL TEXT
Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease
Eshaghian et al.
ANN INTERN MED 2007;146:434-441.
ABSTRACT
| FULL TEXT
Primary PCI for Myocardial Infarction with ST-Segment Elevation
Keeley and Hillis
NEJM 2007;356:47-54.
FULL TEXT
Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice
Zeymer et al.
Eur Heart J 2006;27:2661-2666.
ABSTRACT
| FULL TEXT
Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction.
Ting et al.
ANN INTERN MED 2006;145:610-617.
ABSTRACT
| FULL TEXT
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study
Hallas et al.
BMJ 2006;333:726.
ABSTRACT
| FULL TEXT
Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease
de Oliveira and Bhatt
Eur Heart J Suppl 2006;8:G10-G14.
ABSTRACT
| FULL TEXT
Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention
Hamdalla and Steinhubl
Eur Heart J Suppl 2006;8:G20-G24.
ABSTRACT
| FULL TEXT
Clopidogrel in ST-elevation myocardial infarction
Sabatine
Eur Heart J Suppl 2006;8:G31-G34.
ABSTRACT
| FULL TEXT
Bleeding and management of bleeding
Eikelboom and Hirsh
Eur Heart J Suppl 2006;8:G38-G45.
ABSTRACT
| FULL TEXT
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Hulot et al.
Blood 2006;108:2244-2247.
ABSTRACT
| FULL TEXT
The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: The ECG CLARITY-TIMI 28 Study
Scirica et al.
J Am Coll Cardiol 2006;48:37-42.
ABSTRACT
| FULL TEXT
Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction
Massel
Evid. Based Med. 2006;11:82-83.
FULL TEXT
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Stone and Aronow
Mayo Clin Proc. 2006;81:641-652.
ABSTRACT
| FULL TEXT
The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2006;47:1689-1706.
FULL TEXT
Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough
Steinhubl and Charnigo
JAMA 2006;295:1581-1582.
FULL TEXT
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2006;11:62-62.
FULL TEXT
Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial
Sabatine et al.
Circulation 2005;112:3846-3854.
ABSTRACT
| FULL TEXT
Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology
Bassand et al.
Eur Heart J 2005;26:2733-2741.
ABSTRACT
| FULL TEXT
Clopidogrel Before PCI Reduces Death in STEMI Patients
JWatch Emergency Med. 2005;2005:1-1.
FULL TEXT
JournalScan
Malik
Heart 2005;91:1503-1504.
FULL TEXT
Clopidogrel After Fibrinolysis, Before PCI
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT
Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
Moliterno and Steinhubl
JAMA 2005;294:1271-1273.
FULL TEXT
|
